Cargando…

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

BACKGROUND: Many prostate cancers demonstrate an increased expression of growth factor receptors such as vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) which have been correlated with increased resistance to radiotherapy and poor prognosis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brooks, Colin, Sheu, Tommy, Bridges, Kathleen, Mason, Kathy, Kuban, Deborah, Mathew, Paul, Meyn, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494537/ https://www.ncbi.nlm.nih.gov/pubmed/22967802 http://dx.doi.org/10.1186/1748-717X-7-154

Ejemplares similares

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
por: Bridges, Kathleen A., et al.
Publicado: (2016)

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
por: Bridges, Kathleen A., et al.
Publicado: (2014)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Efficacy of a Selective Binder of α(V)β(3) Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models
por: Sartori, Andrea, et al.
Publicado: (2019)

Effective Antiviral Activity of the Tyrosine Kinase Inhibitor Sunitinib Malate against Zika Virus
por: Lin, Chen-Sheng, et al.
Publicado: (2021)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas
por: Lüttich, Lina, et al.
Publicado: (2021)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
por: Knoerzer, D, et al.
Publicado: (2013)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
por: Sbitti, Yassir, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
por: AlAzab, Rami S, et al.
Publicado: (2019)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Targeting Tyrosine Kinases and Autophagy in Prostate Cancer
por: Kung, Hsing-Jien
Publicado: (2010)

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo
por: Jensen, Brian C., et al.
Publicado: (2017)

Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells
por: Jiang, Yuelong, et al.
Publicado: (2022)

A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib
por: Henderson, Valerie C, et al.
Publicado: (2015)

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation
por: Greenberg, Jacob W., et al.
Publicado: (2022)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
por: Pozo, Karine, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
por: Rozkiewicz, Dariusz, et al.
Publicado: (2023)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

Radiosensitization in prostate cancer: mechanisms and targets
por: Palacios, Diego A, et al.
Publicado: (2013)

Multidisciplinary clinics in prostate cancer
por: De, Brian, et al.
Publicado: (2021)

Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review
por: Ferrari, Elena, et al.
Publicado: (2021)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
por: Ananthula, Hari Krishna, et al.
Publicado: (2018)

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
por: Hsu, Jeff, et al.
Publicado: (2023)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2019)

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity
por: Alamón, Catalina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6hpc3laedqgv2fcpajdvtdn8fb